Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 29:12:654960.
doi: 10.3389/fimmu.2021.654960. eCollection 2021.

Roles of BTLA in Immunity and Immune Disorders

Zhaochen Ning  1   2 , Keyan Liu  3 , Huabao Xiong  1   2
Affiliations
Review

Roles of BTLA in Immunity and Immune Disorders

Zhaochen Ning et al. Front Immunol. .

Abstract

B and T lymphocyte attenuator (BTLA) is one of the most important cosignaling molecules. It belongs to the CD28 superfamily and is similar to programmed cell death-1 (PD-1) and cytotoxic T lymphocyte associated antigen-4 (CTLA-4) in terms of its structure and function. BTLA can be detected in most lymphocytes and induces immunosuppression by inhibiting B and T cell activation and proliferation. The BTLA ligand, herpesvirus entry mediator (HVEM), does not belong to the classic B7 family. Instead, it is a member of the tumor necrosis factor receptor (TNFR) superfamily. The association of BTLA with HVEM directly bridges the CD28 and TNFR families and mediates broad and powerful immune effects. Recently, a large number of studies have found that BTLA participates in numerous physiopathological processes, such as tumor, inflammatory diseases, autoimmune diseases, infectious diseases, and transplantation rejection. Therefore, the present work aimed to review the existing knowledge about BTLA in immunity and summarize the diverse functions of BTLA in various immune disorders.

Keywords: BTLA; HVEM; cancer immunotherapy; coinhibition; inflammation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Bidirectional signaling between BTLA and HVEM. Engagement of BTLA leads to SHP-1 and SHP-2 recruitment in T cells, thereby downregulating TCR signaling and delivering inhibitory signals. The Grb-2 association motif binds to Grb-2, leading to the recruitment of PI3K protein subunit p85 and the stimulation of the PI3K signaling pathway. Additionally, BTLA/HVEM signaling is bidirectional. BTLA/HVEM engagement induces HVEM-mediated NF-κB activation in antigen-presenting cells, thus providing proinflammatory and pro-survival signals.
See this image and copyright information in PMC

References

    1. Sedy JR, Gavrieli M, Potter KG, Hurchla MA, Lindsley RC, Hildner K, et al. . B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol (2005) 6:90–8. 10.1038/ni1144 - DOI - PubMed
    1. Gonzalez LC, Loyet KM, Calemine-Fenaux J, Chauhan V, Wranik B, Ouyang W, et al. . A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator. Proc Natl Acad Sci USA (2005) 102:1116–21. 10.1073/pnas.0409071102 - DOI - PMC - PubMed
    1. Gavrieli M, Watanabe N, Loftin SK, Murphy TL, Murphy KM. Characterization of phosphotyrosine binding motifs in the cytoplasmic domain of B and T lymphocyte attenuator required for association with protein tyrosine phosphatases SHP-1 and SHP-2. Biochem Biophys Res Commun (2003) 312:1236–43. 10.1016/j.bbrc.2003.11.070 - DOI - PubMed
    1. Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, et al. . BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol (2003) 4:670–9. 10.1038/ni944 - DOI - PubMed
    1. Gavrieli M, Murphy KM. Association of Grb-2 and PI3K p85 with phosphotyrosile peptides derived from BTLA. Biochem Biophys Res Commun (2006) 345:1440–5. 10.1016/j.bbrc.2006.05.036 - DOI - PubMed

Publication types

MeSH terms